Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis

Overview

Journal Adv Ther

Date 2024 Mar 23

PMID 38520502

Authors

Benjamin Chastek

Adam Carrera

Christina Landis

Daniel Snyder

Laleh Abedinzadeh

Tim Bancroft

Jeffrey Nesheim

Michael Kennelly

David Staskin

Affiliations

Soon will be listed here.

Abstract

Introduction: Vibegron is a β-adrenergic receptor agonist approved for overactive bladder (OAB). This analysis assessed real-world adherence and persistence with vibegron in patients with OAB, along with demographics and clinical characteristics associated with adherence and persistence.

Methods: This retrospective study used the Optum Research Database to identify patients treated with vibegron from April 2021 to August 2022 (identification period). Patients had ≥ 60 days of continuous pharmacy coverage in a commercial or Medicare Advantage plan following the index fill (follow-up). Adherence was assessed as proportion of days covered (PDC) from index to end of follow-up and was defined as PDC ≥ 80%. Persistence was measured as days to discontinuation of therapy (30-day gap) or end of follow-up. Data for adherence and persistence are presented descriptively. Characteristics associated with adherence and persistence were analyzed using multivariable models among patients with medical and pharmacy benefits during the 90 days before index (baseline).

Results: Overall, 9992 patients had a vibegron claim during the identification period; 9712 had ≥ 2 months of follow-up. Mean (SD) age was 74.2 (10.7) years; 68.2% were female. Mean (SD) PDC was 0.64 (0.34). Median (95% confidence interval) persistence was 142 (132-153) days. Of the 5073 patients who were ≥ 18 years old with continuous baseline pharmacy and medical benefits ≥ 90 days before index, 2497 (49.2%) were adherent. Patients were more likely to be adherent and persistent if they received a greater days' supply for the index fill and had baseline medication count ≥ 6. Patients were more likely to discontinue if their index copay was > $45.

Conclusion: Nearly half of the patients initiating vibegron were adherent. Factors associated with adherence and persistence were more likely to be related to prescribing practices than patient characteristics. These results suggest it may be best to follow up with patients approximately 4 to 5 months after initiating treatment with vibegron.

References

Diokno A, Sand P, MacDiarmid S, Shah R, Armstrong R . Perceptions and behaviours of women with bladder control problems. Fam Pract. 2006; 23(5):568-77. DOI: 10.1093/fampra/cml018. View

Coyne K, Sexton C, Irwin D, Kopp Z, Kelleher C, Milsom I . The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008; 101(11):1388-95. DOI: 10.1111/j.1464-410X.2008.07601.x. View

Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K . Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. Low Urin Tract Symptoms. 2016; 10(2):148-152. DOI: 10.1111/luts.12151. View

Mukai S, Nomi M, Yamada S, Yanagiuchi A, Sengoku A . The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan. Low Urin Tract Symptoms. 2021; 13(4):448-455. DOI: 10.1111/luts.12391. View

Yeaw J, Benner J, Walt J, Sian S, Smith D . Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009; 15(9):728-40. PMC: 10441195. DOI: 10.18553/jmcp.2009.15.9.728. View

Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H, Berner T . Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. J Med Econ. 2014; 17(10):741-50. DOI: 10.3111/13696998.2014.941066. View

Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S . Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017; 71(3-4). PMC: 6680256. DOI: 10.1111/ijcp.12824. View

Balkrishnan R, Bhosle M, Camacho F, Anderson R . Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol. 2006; 175(3 Pt 1):1067-71. DOI: 10.1016/S0022-5347(05)00352-6. View

Melotti I, Juliato C, Tanaka M, Riccetto C . Severe depression and anxiety in women with overactive bladder. Neurourol Urodyn. 2017; 37(1):223-228. DOI: 10.1002/nau.23277. View

10.

Karlsson S, Hero C, Eliasson B, Franzen S, Svensson A, Miftaraj M . Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study. Pharmacoepidemiol Drug Saf. 2017; 26(10):1220-1232. PMC: 5656892. DOI: 10.1002/pds.4281. View

11.

Soda T, Tashiro Y, Koike S, Ikeuchi R, Okada T . Overactive bladder medication: Persistence, drug switching, and reinitiation. Neurourol Urodyn. 2020; 39(8):2527-2534. DOI: 10.1002/nau.24527. View

12.

Anger J, Nissim H, Le T, Smith A, Lee U, Sarkisian C . Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups. Neurourol Urodyn. 2011; 30(7):1295-9. PMC: 3767308. DOI: 10.1002/nau.21004. View

13.

Lua L, Pathak P, Dandolu V . Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017; 36(8):2123-2131. DOI: 10.1002/nau.23256. View

14.

Coyne K, Sexton C, Vats V, Thompson C, Kopp Z, Milsom I . National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77(5):1081-7. DOI: 10.1016/j.urology.2010.08.039. View

15.

Ali M, Grogan S, Powell S, Staniford L, Nazir J, Landeira M . Qualitative Analysis of Factors Influencing Patient Persistence and Adherence to Prescribed Overactive Bladder Medication in UK Primary Care. Adv Ther. 2019; 36(11):3110-3122. PMC: 6822799. DOI: 10.1007/s12325-019-01098-y. View

16.

Song Y, Lee H, Park J, Kim J . Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis. J Urol. 2020; 205(6):1595-1604. DOI: 10.1097/JU.0000000000001440. View

17.

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejon A, Saez-Zafra M, Coll-de Tuero G . Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions. Clin Drug Investig. 2015; 35(12):795-805. DOI: 10.1007/s40261-015-0342-2. View

18.

Zeber J, Manias E, Williams A, Hutchins D, Udezi W, Roberts C . A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health. 2013; 16(5):891-900. DOI: 10.1016/j.jval.2013.04.014. View

19.

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd Jr P . International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J Urol. 2020; 204(2):316-324. DOI: 10.1097/JU.0000000000000807. View

20.

Witticke D, Seidling H, Klimm H, Haefeli W . Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence. 2012; 6:679-84. PMC: 3461601. DOI: 10.2147/PPA.S35950. View